Integer Holdings Co. (NYSE:ITGR) Shares Purchased by Creative Planning

Creative Planning raised its position in Integer Holdings Co. (NYSE:ITGR) by 22.2% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 9,077 shares of the medical equipment provider’s stock after acquiring an additional 1,650 shares during the quarter. Creative Planning’s holdings in Integer were worth $1,180,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Contravisory Investment Management Inc. grew its holdings in Integer by 55.9% during the 3rd quarter. Contravisory Investment Management Inc. now owns 223 shares of the medical equipment provider’s stock valued at $29,000 after purchasing an additional 80 shares in the last quarter. Quest Partners LLC increased its position in shares of Integer by 3,688.9% during the second quarter. Quest Partners LLC now owns 341 shares of the medical equipment provider’s stock worth $39,000 after acquiring an additional 332 shares during the last quarter. GAMMA Investing LLC lifted its stake in shares of Integer by 60.9% in the second quarter. GAMMA Investing LLC now owns 375 shares of the medical equipment provider’s stock worth $43,000 after acquiring an additional 142 shares in the last quarter. Headlands Technologies LLC purchased a new position in Integer in the first quarter valued at about $106,000. Finally, Innealta Capital LLC acquired a new stake in Integer during the 2nd quarter valued at approximately $110,000. Hedge funds and other institutional investors own 99.29% of the company’s stock.

Wall Street Analysts Forecast Growth

ITGR has been the subject of several research analyst reports. KeyCorp increased their target price on Integer from $139.00 to $144.00 and gave the company an “overweight” rating in a research note on Tuesday, October 15th. Piper Sandler reiterated an “overweight” rating and set a $140.00 price objective (up from $125.00) on shares of Integer in a research note on Friday, October 25th. Bank of America boosted their target price on shares of Integer from $135.00 to $145.00 and gave the stock a “buy” rating in a research report on Tuesday, October 1st. Oppenheimer began coverage on shares of Integer in a research report on Tuesday, July 16th. They set an “outperform” rating and a $135.00 price target on the stock. Finally, Truist Financial lowered their price objective on Integer from $150.00 to $147.00 and set a “buy” rating for the company in a report on Friday, October 25th. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $139.75.

Integer Stock Down 4.4 %

Integer stock opened at $124.25 on Friday. Integer Holdings Co. has a 52 week low of $79.68 and a 52 week high of $133.53. The stock has a market cap of $4.16 billion, a price-to-earnings ratio of 42.99, a PEG ratio of 1.80 and a beta of 1.08. The company’s 50-day moving average price is $128.01 and its two-hundred day moving average price is $121.29. The company has a current ratio of 3.29, a quick ratio of 1.96 and a debt-to-equity ratio of 0.73.

Integer (NYSE:ITGR) last issued its quarterly earnings results on Thursday, October 24th. The medical equipment provider reported $1.43 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.36 by $0.07. Integer had a return on equity of 11.48% and a net margin of 6.31%. The firm had revenue of $431.42 million during the quarter, compared to analyst estimates of $440.59 million. During the same period last year, the company posted $1.27 EPS. The firm’s quarterly revenue was up 8.7% on a year-over-year basis. On average, analysts expect that Integer Holdings Co. will post 5.3 EPS for the current fiscal year.

Integer Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.